Statin drugs mitigate cellular inflammatory response after ST elevation myocardial infarction, but do not affect in-hospital mortality

Leili Pourafkari¹², Ognjen Visnjevac¹, Samad Ghaffari¹, Nader D. Nader*²

¹Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
²State University of New York at Buffalo, Buffalo, NY, USA

Abstract

Introduction: The objective was to examine the role of statins in modulating post-STEMI inflammation and related mortality.

Methods: A total of 404 patients with STEMI were reviewed. Demographics, comorbidities, laboratory values, and outcomes were collected. The patients were grouped as STATIN and NOSTAT based on the use of statin drugs at the time of admission. Ninety-seven patients were receiving statin drugs.

Results: The patients in the STATIN group were more likely to be hypertensive (53.6%), diabetic (37.1%) and to have previous coronary revascularization (9.3%). Following propensity matching of 89 patients in STATIN group to an equal number of patients in NOSTAT controls had lower neutrophil count 7.8 (6.8-8.4) compared to those in the NOSTAT group 9.1 (7.9-10.1). Although there was no difference in-hospital mortality between the two groups, the incidence of pump failure was lower in the STATIN group (5.6% vs. 15.7%; P<0.01).

Conclusion: Statin treatment prior to STEMI mitigates the cellular inflammatory response after the myocardial infarction, as evidenced by lower leukocyte and neutrophil cell counts in the STATIN group.

Introduction

Acute ST elevation myocardial infarction (STEMI) is associated with a significant local inflammatory response that is initiated in the myocardium and propagates systemically into the blood stream. Proximal inflammatory cytokines such as tumor necrosis factor alpha (TNFα) and variety of chemokines are scant in healthy hearts, however their levels spike up during myocardial infarct.¹-³ Elevation of acute phase reactants such as C-reactive protein and increased peripheral white blood cell count, especially neutrophils, are common manifests of systemic inflammation during an acute coronary syndrome.⁴-⁵ Various investigators have reported associations between increased neutrophil count in peripheral blood and short-term post-STEMI adverse outcomes, including mortality.⁶-⁸ It has been imperative for both clinicians and researchers in the field of cardiovascular medicine to successfully mitigate the exuberant inflammatory responses during an acute coronary event with the aim of limiting the extent of the myocardial injury and thereby improving the outcome following STEMI.

The use of statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) has been associated with atheroprotective and anti-inflammatory effects, independent of their lipid lowering effects.⁹-¹¹ Their pharmacological action has been attributed to improvements in endothelial function, reduction in smooth muscle cell proliferation and migration and reduction in the number of smooth muscle cells along with a reduction in the collagen content in plaques.¹²,¹³ In the Heart Protection Study, the largest randomized study on the effects of statins on major morbidity and mortality, the authors reported that all-cause mortality was reduced in patients who received statins, primarily due to the reduction in death from vascular causes.¹⁴ There have also been reports on the effects of statin drugs on reducing postoperative morbidity and mortality following various cardiovascular procedures.¹⁵-¹⁷

The goal of this study was to determine if the use of statin drugs was associated with a decrease in inflammatory response, adverse events, and mortality in patients admitted to the coronary care unit with a newly diagnosed STEMI. We hypothesized that the patients who were on statins at
the time of the event had more limited inflammatory response and better survival following a STEMI.

**Patients and Methods**

After obtaining informed consent, a total of 404 patients who were admitted to the Coronary Care Unit with acute STEMI were enrolled from March 2010 to March 2012. Patients were assigned to the statin (STATIN) group, or the no statin (NOSTAT) group depending on whether they were receiving statin therapy at the time of the STEMI, or not. Patients who were on statins at the time of STEMI were already started on these drugs by their primary providers, but the exact duration of statin drug use was not available for this study. Patients with active inflammation or chronic inflammatory diseases, past history of surgery within 3 months prior to STEMI, and cancer were excluded from the study. STEMI was determined using the definition and criteria provided by American College of Cardiology and European Society of Cardiology; in short: STEMI was defined as an increase in cardiac troponin-I (cTNI) along with new ST-segment elevation measured from J point at least 0.2 mV in two adjacent V1-V3 leads or at least 0.1 mV in other leads within 24 hours after the onset of chest pain.16

The information regarding demographic features, past medical history, patient outcomes and the occurrence of major complications or mortality were collected from the medical records for all subjects. Complete blood cell count was performed in all patients within 24 hours of onset of symptoms. Blood samples were evaluated for total leukocyte, neutrophil, lymphocyte and monocyte count using SE-2100 Scattergram (Sysmex, Mundelein, IL). The neutrophil lymphocyte ratio was calculated for each patient. The following laboratory values were collected for all patients: hematocrit, creatinine, creatine kinase (CK) with MB fraction (CKMB) and cTNI. The peak values were documented and reported for all laboratory variables.

Hypertension was defined as blood pressure of ≥140/90 mm Hg recorded at least two times or current antihypertensive therapy. Diabetes was defined as fasting plasma glucose of >126 mg/dL for at least two measurements or current glucose lowering treatment as defined by the World Health Organization (WHO).15 Renal insufficiency was defined as having a serum creatinine higher than 1.5 mg/dL or greater, or a patient on dialysis. Hyperlipidemia was defined as fasting cholesterol level >200 mg/dL, a low-density lipoprotein level >130 mg/dL, or triglycerides >200 mg/dL before starting on lipid-lowering therapy.

**Statistical analyses and data management**

Data analysis was performed using SPSS 18.0 software (SPSS Inc, Chicago, IL) and NCSS (Kaysville, Utah). Primary endpoints were peak leukocyte and neutrophil counts, and in-hospital mortality. Secondary endpoints included pump failure (defined as cardiogenic shock and/or pulmonary edema), ICU length of stay and major tachyarrhythmias (defined as atrial fibrillation and ventricular tachycardia or fibrillation). Demographic comparisons were made using chi-square, or two-tailed Fisher’s exact test for categorical variables, and by Wilcoxon Rank-Sum test for continuous variables without normality distribution. Univariate analysis was performed using log-rank test for identifying factors predicting in-hospital mortality. All factors that show a trend of significance as identified by P values <0.1 in univariate analyses were included in multivariate analyses. Propensity scores were calculated using hypertension, diabetes, unstable angina and previous coronary revascularization. Since the majority of hyperlipidemia patients were in the STATIN group, this variable was not used for matching. Doing so would have eliminated majority of the patients who were receiving statins. Data were then matched (1:1) using the calculated propensity scores for the STATIN cohort and NOSTAT controls. Odds ratios were reported for 2×2 tests and 95% confidence interval for event endpoints analyses. Null hypotheses were rejected if P values were less than 0.05.

**Results**

Of the 404 patients enrolled in this study, 97 were taking statins at the time of STEMI. Patients in the STATIN group had significantly more hyperlipidemia, hypertension, diabetes mellitus, and prior revascularizations along with a higher blood glucose concentration on admission. After propensity matching, there were no statistical differences in demographics, comorbidities, or laboratory values between the two groups, except for hyperlipidemia, which remained statistically higher in the STATIN group as this variable was not included in the propensity matching calculation (Table 1).

Before propensity matching, sequelae following STEMI were similar between the two groups except for peak cTNI, which was higher in the NOSTAT group (4.6 ng/ml, 95% CI: 3.2-6.4) than in the STATIN group (2.3 ng/ml, 95% CI: 0.9-4.5, P = 0.043). CK and CKMB both displayed a strong trend toward significance, having non-significant p-values with a 2-tailed analyses and statistical significance with the 1-tailed analyses (Table 2). After propensity matching, these markers of cardiac ischemia were no longer found to be statistically different between groups, but there was a lower incidence of pump failure (OR=0.39, 95% CI: 0.11-0.93, P = 0.036) (Table 3). Overall in hospital mortality was low (15 patients, 3.71% of total sample) and it was not significantly different between the STATIN (OR=0.59, 95% CI: 0.14-2.53, P = 0.474) and NOSTAT groups.

The inflammatory response following STEMI was statistically different before and after propensity matching, with a post-matched increase in leukocyte (P = 0.001) and neutrophil (P = 0.002) count in the NOSTAT group (Table 4). There were no differences in monocyte or lymphocyte counts and the neutrophil-lymphocyte ratio was not statistically different between groups after propensity matching (Table 4). Neutrophil count was not associated with an improvement in survival (OR = 0.95, 95% CI: 0.30-3.00, P = 0.925)
Discussion
Statin drugs were found to mitigate the cellular inflammatory response after ST elevation myocardial infarction, as evidenced by statistically lower leukocyte and neutrophil cell counts in the STATIN group, without evidence of differences in monocyte or lymphocyte cell counts. This is an important finding as it may provide the pathophysiological evidence that anti-inflammatory effects of statins and mortality benefit are the direct result of mitigated neutrophil activation during acute coronary syndromes. Although the effect of statins on in-hospital mortality could not effectively be examined in this study because of its low occurrence rate (3.71% of the overall sample) and relatively short follow-up period, other studies have provided strong evidence that statins carry a mortality benefit and that peripheral neutrophilia is associated with worse cardiovascular outcomes, with this study providing evidence of a connection between the two (statins and neutrophilia).

Associated neutrophilia following acute myocardial infarction may indeed be related to decreased margination of neutrophils. This phenomenon has been ascribed in these patients due to increased circulating levels of catecholamines. The effects of statin drugs on endothelial cell function and vascular smooth muscles may restore the margination of the neutrophils and contribute to the

### Table 1. Patient demographics, comorbidities, and laboratory data

| Variable                        | Before Propensity Match | After Propensity Match |
|--------------------------------|-------------------------|------------------------|
|                                | STATN n=97              | NOSTAT n=307           | P value |
|                                |                         |                        | STATN n=89 | NOSTAT n=89 | P value |
| Age*                           | 61.5[56-65]             | 57.0[55-60]            | 0.32      | 61[56-65]   | 60[56-65] | 0.50 |
| Female**                       | 23(23.7)                | 53(17.3)               | 0.16      | 22(24.7)    | 23(25.8) | 0.86 |
| Family history                 | 24(24.7)                | 63(20.5)               | 0.38      | 22(24.7)    | 13(14.6) | 0.09 |
| Hyperlipidemia                 | 82(84.5)                | 32(10.4)               | <0.01     | 81(91)      | 13(14.6) | <0.01 |
| Hypertension                   | 52(53.6)                | 105(34.2)              | <0.01     | 47(52.8)    | 46(51.7) | 0.88 |
| Diabetes mellitus              | 36(37.1)                | 65(21.2)               | <0.01     | 34(38.2)    | 35(39.3) | 0.88 |
| Active smoker                  | 36(37.1)                | 144(46.9)              | 0.09      | 35(39.3)    | 32(36.0) | 0.64 |
| Stroke                         | 4(4.1)                  | 17(5.5)                | 0.59      | 4(4.5)      | 9(10.1)  | 0.15 |
| Unstable angina                | 3(3.1)                  | 26(8.5)                | 0.07      | 3(3.4)      | 3(3.4)   | 1.00 |
| Myocardial infarction          | 11(11.3)                | 21(6.8)                | 0.15      | 8(9.0)      | 7(7.9)   | 0.79 |
| Prior revascularization        | 9(9.3)                  | 2(0.7)                 | <0.01     | 1(1.1)      | 1(1.1)   | 1.00 |
| LVEF*                          | 40[35-40]               | 40[40-40]              | 0.82      | 40[35-40]   | 40[30-40] | 0.29 |
| Length of hospital stay (days) | 7[6-7]                  | 6[5-6]                 | 0.06***   | 6[6-7]      | 6[6-7]   | 0.89 |
| Hematocrit %                   | 43.6[42.3-44.7]         | 43.0[42.3-43.8]        | 0.44      | 43.7[42.3-44.7] | 42.1[41.0-43.5] | 0.09*** |
| Creatinine mg/dL               | 0.93[0.85-1]            | 0.93[0.9-0.97]         | 0.75      | 0.93[0.85-1] | 0.97[0.9-1] | 0.37 |
| Blood glucose (mg/dL)          | 157[136-180]            | 142[134-146]           | 0.05      | 156[135-174] | 155[136-175] | 0.71 |

* Median [range]; Wilcoxon Rank-Sum 2-tailed test used to calculate P value.
** n (%); Chi-squared used to calculate P value.
*** Although 2-tailed test showed non-significance, a 1-tailed test indicated significance.

### Table 2. Post-STEMI sequelae (not propensity matched)

| Clinical/laboratory outcome                          | STATN n=97 | NOSTAT n=307 | P value |
|------------------------------------------------------|-------------|--------------|---------|
| Ventricular Dysrhythmias within 24 hours**           | 4(4.1)      | 25(8.1)      | 0.181   |
| Ventricular Dysrhythmias after 24 hours**            | 2(2.1)      | 6(2.0)       | 0.947   |
| New right bundle branch block**                      | 8(8.2)      | 32(10.4)     | 0.532   |
| New left bundle branch block**                       | 5(5.2)      | 9(2.9)       | 0.297   |
| Atrial fibrillation**                                | 5(5.2)      | 15(4.9)      | 0.915   |
| Paroxysmal supraventricular tachycardia**            | 0(0)        | 6(2.0)       | 0.165   |
| 1st or 2nd degree AV block**                         | 5(5.2)      | 19(6.2)      | 0.934   |
| Complete AV block**                                 | 2(2.1)      | 4(1.3)       | 0.590   |
| Ventricular septal defect**                          | 1(1.0)      | 1(0.3)       | 0.388   |
| Mitral regurgitation**                               | 7(7.2)      | 20(6.5)      | 0.809   |
| Pulmonary edema**                                    | 3(3.1)      | 18(5.9)      | 0.284   |
| Pump failure**                                       | 6(6.2)      | 29(9.4)      | 0.320   |
| Repeat in-hospital myocardial infarction**           | 1(1.0)      | 3(1.0)       | 0.963   |
| In-hospital mortality**                              | 4(4.1)      | 11(3.6)      | 0.806   |
| Creatine kinase (units)*                             | 524[282-1038]| 922[692-1199]| 0.070***|
| Creatine kinase MB isoenzyme (units)*                | 60[47-89]   | 91[72-112]   | 0.080***|
| Cardiac troponin I (nanogram/mL)*                    | 2.3[0.9-4.5] | 4.6[3.2-6.4] | 0.043   |

* Median [range]; 2-tailed Wilcoxon Rank-Sum test used to calculate P value.
** n (%); Chi-squared used to calculate P value.
*** Although 2-tailed test showed non-significance, a 1-tailed test indicated significance.
Statins inhibit the inflammatory response following STEMI

Table 3. Post-STEMI sequelae (propensity matched)

| Clinical/Laboratory Outcome                  | STATN N=89 | NOSTAT N=89 | P-Value |
|---------------------------------------------|------------|-------------|---------|
| Ventricular dysrhythmias within 24 hours**  | 3[3.4]     | 5[5.6]      | 0.469   |
| Ventricular dysrhythmias after 24 hours**   | 2[2.2]     | 1[1.1]      | 0.561   |
| New right bundle branch block**             | 7[7.9]     | 12[13.5]    | 0.225   |
| New left bundle branch block**              | 4[4.5]     | 3[3.4]      | 0.700   |
| Atrial fibrillation**                       | 5[5.6]     | 6[6.7]      | 0.756   |
| Paroxysmal supraventricular tachycardia**   | 0(0)       | 1[1.1]      | 0.316   |
| 1st or 2nd degree AV block**                | 5[5.6]     | 5[5.6]      | 1.000   |
| Complete AV block**                         | 2[2.2]     | 2[2.2]      | 1.000   |
| Ventricular septal defect**                 | 1[1.1]     | 0(0)        | 0.316   |
| Mitral regurgitation**                      | 7[7.9]     | 4[4.5]      | 0.350   |
| Pulmonary edema**                          | 3[3.4]     | 10[11.2]    | 0.044   |
| Pump failure**                              | 5[5.6]     | 14[15.7]    | 0.023   |
| Repeat in-hospital myocardial infarction**  | 0(0)       | 1[1.1]      | 0.316   |
| In-hospital mortality**                     | 3[3.4]     | 5[5.6]      | 0.469   |
| Creatine kinase (units)*                    | 601[353-1126] | 889[504-1204] | 0.386   |
| Creatine kinase MB isoenzyme (units)*       | 61[49-94]  | 81[63-119]  | 0.780   |
| Cardiac troponin I (nanogram/mL)*           | 2.5[1.2-6.2] | 6.2[1.5-10.4] | 0.145   |

* Median [range]; 2-tailed Wilcoxon Rank-Sum test used to calculate P value.
** n(%); Chi-squared used to calculate P value.
*** Although 2-tailed test showed non-significance, a 1-tailed test indicated significance.

Table 4. Leukocytic inflammatory response following STEMI

| Variable                  | Before Propensity Match | After Propensity Match |
|---------------------------|-------------------------|------------------------|
|                           | STAT N=97               | NOSTAT N=307           |         |
|                           | STAT N=89               | NOSTAT N=89            |         |
|                           | P value                 | P value                |         |
| Total leukocyte count     | 9.9[9.2-10.7]           | 11.0[10.6-11.6]        | 0.001   |
| Neutrophils               | 7.3[6.7-8.4]            | 8.6[8.1-9.1]           | 0.001   |
| Lymphocytes               | 1.4[1.3-1.6]            | 1.4[1.3-1.4]           | 0.364   |
| Monocytes                 | 0.61[0.53-0.67]         | 0.62[0.58-0.65]        | 0.402   |
| Neutrophil/lymphocyte     | 5.0[4.0-6.1]            | 5.9[5.2-6.6]           | 0.035   |

Values presented as Median [range]; 2-tailed Wilcoxon Rank-Sum test used to calculate P value.

lower count of these inflammatory cells in the peripheral blood. Although the contribution of statins to the endothelium-neutrophil interaction during STEMI is beyond the scope of this study, this mechanism of action may have some theoretical value. Cholesterol-independent or “pleiotropic” effects of statins are thought to protect against myocardial injury and may occur via a number of mechanisms including their effect on endothelial function.

A recent systematic review of the routine use of high-flow oxygen in the treatment of uncomplicated myocardial infarction found that its routine use might result in a greater infarct size and increase the risk of mortality. These findings are supported by direct physiologic evidence of the phenomenon of hyperoxia-mediated coronary vasoconstriction, but hyperoxic-cardiac injury may not be limited to this mechanism. Hyperoxia also affects the redox cellular state of ischemic myocardium, fuels the abundance of reactive oxygen species generated by the neutrophilia of acute coronary syndromes, and has been implicated in exacerbating oxygen radical-mediated reperfusion injury following coronary revascularization. The concurrent effect of statin use for mitigating elements of hyperoxic-injury in the context of neutrophilia and oxygen radical formation was not assessed in our study, nor any other to date.

This study also found a higher incidence of pump failure in the NOSTAT group, but the etiology of this remains unclear. Although a greater degree of myocardial injury, as evidenced by higher mean blood concentrations of cardiac markers of ischemia in the NOSTAT group (Table 3), may infer a logical explanation, the wide range of cardiac marker values in this population sample yielded non-statistically significant differences between the two study groups. There were no statistically significant differences in major tachyarrhythmias, new-onset conduction delays, new-onset mitral regurgitation, or recurrent in-hospital myocardial infarction between the two groups. The extent of mitral regurgitation was not documented, however, and may have contributed to the higher incidence of pump failure and pulmonary edema in the NOSTAT group. There were several limitations to this study. First, during propensity matching process, it was evident the majority of patients diagnosed with hyperlipidemia were in the statin group and could not be effectively matched without excessively compromising the post-propensity matched
sample size. It is also possible that there were patients without this hyperlipidemia diagnosis in each group that were, in fact, hyperlipidemic but had not yet been diagnosed as such.

Second, this study’s primary endpoint of in-hospital mortality yielded low numbers and limited statistical analysis. Others have described long-term mortality to be significantly higher than was found in this study, but this study did not follow patients or assess their outcomes following hospital discharge.26 Furthermore, the post-STEMI day of mortality was not recorded in this study, nor was there any assessment of all-cause mortality following hospital discharge.

This study’s major finding was that statins mitigate the cellular inflammatory response following STEMI which directly influences and focuses future research. The subcellular and intercellular pathways by which statins exert this effect need to be elucidated. Neutrophil mediated cellular injury is a function of blunt mechanisms (oxygen radical production, lytic enzyme utilization, and phagocytosis) combined with directed extravasation and targeting, identifying several potential areas of immunologic modifiable risk factors in the post-STEMI period.27 Statins’ effects on neutrophil-mediated reperfusion injury are also yet to be elucidated.

**Ethical issues**

This study was approved by the Institutional Review Board of Tabriz University of Medical Sciences for its scientific and ethical merit.

**Competing interests**

None.

**References**

1. Arras M, Hoche A, Bohle R, Eckert P, Riedel W, Schaper J. Tumor necrosis factor-alpha in macrophages of heart, liver, kidney, and in the pituitary gland. Cell Tissue Res 1996; 285: 39-49.

2. Frangogiannis NG, Perrard JL, Mendoza LH, Burns AR, Lindsey ML, Ballantyne CM, et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation 1998; 98: 687-98.

3. Aker S, Belosjorow S, Konietzka I, Duschin A, Martin C, Heusch G, et al. Serum but not myocardial TNF-alpha concentration is increased in pacing-induced heart failure in rabbits. Am J Physiol Regul Integr Comp Physiol 2003; 285: R463-9. doi: 10.1152/ajpregu.00153.2003.

4. Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102: 2329-34.

5. Bursi F, Weston SA, Killian JM, Gabriel SE, Jacobsen SJ, Roger VL. C-reactive protein and heart failure after myocardial infarction in the community. Am J Med 2007; 120: 616-22. doi: 10.1016/j.amjmed.2006.07.039

6. Ghaffari S, Golmohammadi A. Correlation between neutrophilia and congestive heart failure after acute myocardial infarction. Med J Ardabil Uni Med Sci 2006; 5: 352-7.

7. Kirtane AJ, Bui A, Murphy SA, Barron HV, Gibson CM. Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction. Am J Cardiol 2004; 93: 532-6. doi: 10.1016/j.amjcard.2003.11.013

8. O’Donoghue M, Morrow DA, Cannon CP, Guo W, Murphy SA, Gibson CM, et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J 2008; 29: 984-91. doi: 10.1093/eurheartj/ehn112

9. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.

10. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherosclerosis. J Am Coll Cardiol 2004; 44: 2293-300. doi: 10.1016/j.jacc.2004.07.060

11. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-21.

12. Fukumoto Y, Libby P, Rabkin E, Hill CC, Enomoto M, Hirouchi Y, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-9.

13. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36. doi: 10.1161/01.ATV.0000063385.12476.A7

14. Heart Protection Study Collaborative G. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22. doi: 10.1016/S0140-6736(02)09327-3

15. Parakasva KI, Athyros VG, Briana DD, Kakafika AI, Karagiannis A, Mikhailidis DP. Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 2007; 8: 942-51.

16. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22.
17. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. J Vasc Surg 2004; 39: 967-75; discussion 75-6. doi: 10.1016/j.jvs.2004.01.004

18. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.

19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.

20. Sundblad AS. [The margination of polynuclear leukocytes in the early diagnosis of acute myocardial infarction]. Medicina (B Aires) 1982; 42: 469-74.

21. Yamakuchi M, Greer JJ, Cameron SJ, Matsushita K, Morrell CN, Talbot-Fox K, et al. HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res 2005; 96: 1185-92. doi: 10.1161/01.RES.0000170229.49776.81

22. Scalia R. Statins and the response to myocardial injury. Am J Cardiovasc Drugs 2005; 5: 163-70.

23. Wijesinghe M, Perrin K, Ranchord A, Simmonds M, Weatherall M, Beasley R. Routine use of oxygen in the treatment of myocardial infarction: systematic review. Heart 2009; 95: 198-202. doi: 10.1136/hrt.2008.148742

24. McNulty PH, Robertson BJ, Tulli MA, Hess J, Harach LA, Scott S, et al. Effect of hyperoxia and vitamin C on coronary blood flow in patients with ischemic heart disease. J Appl Physiol 2007; 102: 2040-5. doi: 10.1152/japplphysiol.00595.2006

25. Kaneda T, Ku K, Inoue T, Onoe M, Oku H. Postischemic reperfusion injury can be attenuated by oxygen tension control. Jpn Circ J 2001; 65: 213-8.

26. Brodie B, Pokharel Y, Fleishman N, Bensimhon A, Kissling G, Hansen C, et al. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovascular Interventions. 2011;4(1):30-8. doi: 10.1016/j.jcin.2010.11.004.

27. Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol. 2011;32(10):452-60. doi: 10.1016/j.it.2011.06.008.